Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 3/20 | 0.35 |
| ▸ | GABRD | O14764 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162198 | 0.91 | OPRK1 (0.36) | EGFRKDROPRK1OPRM1MKNK1 | |
| SCHEMBL30011674 | 0.91 | OPRK1 (0.36) | EGFRKDROPRK1OPRM1MKNK1 | |
| SCHEMBL18386904 | 0.91 | KDR (0.40) | EGFRKDRCCNT1CDK9GABRP | |
| SCHEMBL18386897 | 0.90 | KDR (0.40) | EGFRKDRMKNK1 | |
| SCHEMBL18387042 | 0.85 | EGFR (0.49) | EGFRKDROPRM1 | |
| SCHEMBL18387037 | 0.85 | EGFR (0.39) | EGFRKDRMKNK2MKNK1CCNT1 | |
| SCHEMBL30010922 | 0.85 | EGFR (0.42) | EGFRKDROPRK1OPRM1MKNK2 | |
| SCHEMBL18386955 | 0.85 | EGFR (0.42) | EGFRKDROPRK1OPRM1MKNK2 | |
| SCHEMBL20162222 | 0.84 | KDR (0.36) | EGFRKDRMKNK1 | |
| SCHEMBL30010761 | 0.84 | KDR (0.36) | EGFRKDRMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3323817-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-05-23 | — | — | EP | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017008761-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | 正大天晴药业集团股份有限公司 | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | EGFR 1/4885KDR 51/4885OPRK1 2567/4885 |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | EGFR 1/4885KDR 51/4885OPRK1 2567/4885 |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | EGFR 1/4885KDR 51/4885OPRK1 2567/4885 |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 44/4885OPRK1 2572/4885 |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 12/4885OPRK1 1049/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | EGFR 1/4885KDR 39/4885OPRK1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.